Mölnlycke
Investor relations
At Mölnlycke, we're driven by a passion for improving healthcare outcomes through innovation and excellence. We are transparent about our strategic objectives, financial performance, and commitment to sustainable growth. We deeply appreciate your interest and trust in Mölnlycke. Your support fuels our mission to make a meaningful impact in healthcare and deliver long-term value to our shareholders.
Mölnlycke key performance figures 2024
-
0 %organic growth
-
0EBIDTA, million EUR
-
0annual sales, million EUR
"Our strong financial position and continued growth allow us to direct our future and continued investments."
Zlatko Rihter Chief Executive Officer
In 2024, Mölnlycke has had another strong year, achieving 2,064 MEUR in net sales while improving profitability. This corresponds to a sales growth of 7% compared to 2023, outperforming the market. Financially, the company has improved on the strong performance of last year, with all business areas showing growth.
Furthermore, Mölnlycke continued to enhance its profitability, achieving and EBITDA of EUR 591 million with a corresponding margin of 29%.
Financial information
-
Financial reporting
-
Mölnlycke Annual report
We are transparent about our impact on environment, people and society. Each year, we report on results and performance in the integrated Annual Report.
Mölnlycke integrated Annual Report 2024 covers the year ending on 31 December 2024. The report has been prepared in accordance with Global Reporting Initiative (GRI) standards, in addition to the Taskforce on Climate related Financial Disclosures (TCFD) framework. Additionally, the report has been structured to align with the Corporate Sustainability Reporting Directive (CSRD) format and requirements, though full compliance has not yet been achieved.
-
Investor presentations
-
Capital Markets Day
Capital Markets Day 2023 Presentation
-
Debt financing
Mölnlycke’s financial risk management is centralised to capitalise on economies of scale, synergy effects and to minimise operational risks.
The Group Treasury function is responsible for the group’s borrowing, liquidity management, currency and interest risks and acts as the internal bank for the group. In addition to ensuring that Mölnlycke has secure financing, financial transactions are conducted with the aim of limiting the Group's financial risks by, for example, diversifying the maturity profile.
Mölnlycke issues notes on the European bond market under its Euro Medium Term Note (EMTN) programme. Mölnlycke has an outstanding debt of EUR 1,800 million and USD 400 million which is long-dated and evenly distributed.
In addition to its own liquidity, Mölnlycke has a syndicated multi-currency revolving credit facility of EUR 350 million (unutilised). It was signed in 2023 as a 5+1+1 agreement. Mölnlycke has chosen to execute both the extension options in 2024 and 2025. Final maturity date is 2030. The facility is backed by a group of seven leading global and regional banks, well diversified to match Mölnlycke’s geographical footprint. The banks are BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB.
Debt programmes
-
EMTN Prospectus dated 13 June 2022.pdf
Download now -
First supplement to the Base Prostectus 2022.pdf
Download now -
EMTN Prospectus dated 13 June 2023.pdf
Download now -
First supplement to the Base Prostectus 2023.pdf
Download now -
EMTN Prospectus dated 24 May 2024.pdf
Download now -
EMTN Prospectus dated 20 May 2025.pdf
Download now
-
-
Credit rating
The purpose of credit ratings is to rank the capability of a company to repay loans - short term and long term - at the time of the maturity of the loan. Mölnlycke is rated by S&P who assigned a long term rating to Mölnlycke of BBB- with a stable outlook, which was latest confirmed in August 2025.
S&P outlook dated August 2025:
The stable outlook on Mölnlycke reflects our view that the company's leading market positions and well-known brands should enable it to sustain positive revenue growth and earnings generation, despite the uncertain economic environment. The outlook also reflects our base case assumption that Mölnlycke will manage its discretionary cash flow, which mainly comprises cash dividends, and maintain debt to EBITDA comfortably between 3x-4x.
-
Board of Directors
Mölnlycke’s Board of Directors has the ultimate responsibility for the company and its operations.
Board of Directors -
Executive Leadership Team
Defines and implements the company’s corporate strategy and ensures day-to-day management of their operations.
Executive Leadership Team -
Our Owner
Investor AB acquired Mölnlycke in 2007. Mölnlycke is the largest wholly-owned subsidiary within Patricia Industries.
Our Owner
Latest news
-
High burnout among operating room staff poses significant risk to patient safety—new review reveals
Gothenburg, Sweden. 17 September 2025. A new narrative review published in the current issue of Journal of Patient Safety, titled ’Putting Patients at Risk: The Effect of Health Care Provider Burnout on Patient Care in the Operating Room’ reveals alarmingly high levels of burnout among healthcare workers in operating rooms (ORs) and warns of the serious implications for staff well-being, care quality and ultimately patient safety.
-
Mölnlycke awarded second consecutive EcoVadis Platinum medal for sustainability performance
Gothenburg, Sweden. 21 August 2025. Mölnlycke®, a world-leading MedTech company, has once again been recognised as a global sustainability leader, earning the prestigious EcoVadis Platinum medal for the second year in a row.
-
New study highlights the importance of double gloving with indicator systems
A new peer-reviewed study published in the Journal of Hospital Infection underscores the critical role of double gloving and indicator systems in reducing the risk of undetected glove breaches during surgery.
-
Mölnlycke Health Care makes record investment to increase global manufacturing capacity with expansion in Maine, USA
Gothenburg, Sweden, 26 June 2025. Mölnlycke Health Care, a global leader in MedTech, today announces its largest investment to date: a €115 million expansion of its wound care manufacturing capacity in Brunswick, Maine, USA.
-
Mölnlycke Health Care secures USD 400 Million in financing from SEK to support global expansion strategy
Stockholm/Gothenburg – 24 June, 2025. Mölnlycke Health Care and The Swedish Export Credit Corporation (SEK) have signed a USD 400 million financing agreement to support the healthcare company’s continued global growth and development.
-
Mölnlycke advocates a holistic approach to healthcare sustainability
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.
-
Mölnlycke Health Care unveils new headquarters at GoCo Health Innovation City, marking a new era of collaboration and innovation
-
Tamer Mölnlycke Care celebrates a new chapter in healthcare in the Kingdom of Saudi Arabia
-
Filippa Stenberg joins Mölnlycke Board of Directors